AC Immune SA (ACIU)
3.29
+0.05
(+1.54%)
USD |
NASDAQ |
Nov 21, 16:00
3.285
0.00 (0.00%)
Pre-Market: 20:00
AC Immune Total Liabilities (Quarterly): 135.61M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 135.61M |
| June 30, 2024 | 126.94M |
| March 31, 2024 | 25.05M |
| December 31, 2023 | 26.40M |
| September 30, 2023 | 18.93M |
| June 30, 2023 | 18.79M |
| March 31, 2023 | 17.75M |
| December 31, 2022 | 18.28M |
| September 30, 2022 | 15.90M |
| June 30, 2022 | 14.64M |
| March 31, 2022 | 23.17M |
| December 31, 2021 | 32.23M |
| September 30, 2021 | 25.87M |
| June 30, 2021 | 23.68M |
| March 31, 2021 | 21.81M |
| December 31, 2020 | 26.63M |
| September 30, 2020 | 25.41M |
| June 30, 2020 | 23.55M |
| Date | Value |
|---|---|
| March 31, 2020 | 23.57M |
| December 31, 2019 | 27.67M |
| September 30, 2019 | 23.17M |
| June 30, 2019 | 23.48M |
| March 31, 2019 | 71.34M |
| December 31, 2018 | 19.23M |
| September 30, 2018 | 17.07M |
| June 30, 2018 | 17.20M |
| March 31, 2018 | 14.88M |
| December 31, 2017 | 15.58M |
| September 30, 2017 | 13.15M |
| June 30, 2017 | 10.88M |
| March 31, 2017 | 11.54M |
| December 31, 2016 | 13.48M |
| September 30, 2016 | 14.98M |
| June 30, 2016 | 13.00M |
| March 31, 2016 | 9.187M |
| December 31, 2015 | 8.992M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
14.64M
Minimum
Jun 2022
135.61M
Maximum
Sep 2024
33.59M
Average
23.63M
Median
Total Liabilities (Quarterly) Benchmarks
| CRISPR Therapeutics AG | 316.47M |
| Addex Therapeutics Ltd | 1.164M |
| NLS Pharmaceutics Ltd | 10.46M |
| Molecular Partners AG | 18.34M |
| MoonLake Immunotherapeutics | 22.71M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 290.33M |
| Shareholders Equity (Quarterly) | 154.72M |
| Current Ratio | 1.858 |